Tariff threats are driving US manufacturing expansion among major pharmaceutical companies like Biogen, Eli Lilly, Roche, and Merck.
4 reports, 3 independent
Updated Jul 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tariff threats are driving US manufacturing expansion among major pharmaceutical companies like Biogen, Eli Lilly, Roche, and Merck.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Eli Lilly and Merck are responding to tariff threats by building new plants and expanding production in the US.1 source
Biogen and Merck respond to tariff threats by investing in US manufacturing.1 source
Major pharma companies are expanding US production capacity due to tariff threats.1 source
Keep exploring
Part of
Trump has threatened the use of tariffs to incentivize companies to move production back to the United States, impacting pharmaceutical imports.Also in this story
- Trump, Overton, and Lutnick advocate for policy shifts including reshoring pharmaceutical production and moving clinical trials to the US, citing national security.
- Pfizer's market outlook is being tied to the effects of Trump-era tariffs and onshoring trends.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Biogen
American multinational biotechnology company
Nothing else this week.
-
Merck
public company in Indonesia
Related events
Coverage
Newest first; wire copies grouped- newkerala.com
- Asheville Citizen-TimesBiogen beefs up North Carolina manufacturing ahead of potential Trump tariff Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, a
- ReutersBiogen beefs up North Carolina manufacturing ahead of potential drug tariff storm (Reuters) -Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker s